April 19, 2014 9:02 PM ET

Capital Markets

Company Overview of Versant Ventures, Inc.

Company Overview

Versant Ventures is a venture capital firm specializing in incubation, seed, start-ups, and early stage investments. It seeks to invest in all segments of healthcare including, medical devices and diagnostics; life sciences that include biopharmaceuticals and biotechnology platforms; healthcare services; and healthcare information technology. The firm prefers to invest in companies based in the United States and Western Europe. The firm seeks to invest in the biotechnology sector in Canada. The firm typically invests between $10 million and $20 million into each startup before it’s sold or goes public. It will not invest in a company unless it has at least $500 million in annualized potentia...

3000 Sand Hill Road

Building 4

Suite 210

Menlo Park, CA 94025

United States

Founded in 1999

Phone:

650-233-7877

Fax:

650-854-9513

Key Executives for Versant Ventures, Inc.

Managing Director
Managing Director
Age: 58
Managing Director
Managing Director
Age: 60
Managing Director
Age: 67
Compensation as of Fiscal Year 2013.

Versant Ventures, Inc. Key Developments

Versant Ventures, Inc. Presents at Biotech Showcase 2014, Jan-15-2014 08:00 AM

Versant Ventures, Inc. Presents at Biotech Showcase 2014, Jan-15-2014 08:00 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Carlo Rizzuto, Operating Principal.

Versant Ventures Expands into Canada to Invest in Innovative, Early-Stage Drug Discoveries and Accelerate Commercialization of Scientific Research

Versant Ventures is expanding operations into Canada to invest in early-stage drug discovery programs and establish new life science companies that can accelerate the commercialization of scientific research in Canada. Versant has already established an office and created an Inception Sciences drug discovery engine in Vancouver to launch new companies. Inception Sciences recently joined forces with Bayer Healthcare to develop innovative therapeutics for retinal eye disease. Versant committed a $10 million Series A investment alongside research funding from Bayer to a new biotech company called Inception 4. The management team at Versant is planning on launching a similar unit in Montreal in 2014. Versant recently formed a biotechnology incubator in Toronto, called Blueline Bioscience, which is collaborating with Celgene and aims to launch new companies in areas such as oncology and inflammation. Blueline Bioscience is headquartered in the MaRS Discovery District of Toronto.

Versant Ventures, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 03:30 PM

Versant Ventures, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 03:30 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States. Speakers: Brian G. Atwood, Managing Director.

Similar Private Companies By Industry

Company Name Region
Vanport Acquisition IV, Corp. United States
Global American Investments, Inc. United States
CKCapital Partners, LLC United States
Concorde Investment Services, LLC United States
Winch Financial, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 16, 2014
ForSight VISION5, Inc.
Private Placement
April 15, 2014
AAVLife
Private Placement
April 2, 2014
Holaira Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Versant Ventures, Inc., please visit www.versantventures.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.